Super-voltage PRF of Stellate Ganglion Versus Super-voltage PRF of T2 T3 Sympathetic Ganglia in Managing PMPS.
Not yet recruitingNot applicableNCT07675096
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aim of this study is to compare the effectiveness of super-voltage pulsed radiofrequency of stellate ganglion and super-voltage pulsed radiofrequency of T2-T3 sympathetic ganglia in the treatment of postmastectomy pain syndrome.
Study details
- Official title
- Super-voltage Pulsed Radiofrequency of Stellate Ganglion Versus Super-voltage Pulsed Radiofrequency of T2 T3 Sympathetic Ganglia in Managing Postmastectomy Pain Syndrome.
- Conditions
- Post Mastectomy Pain Syndrome
- Chronic Pain Following Surgical Procedure for Cancer
- Interventions
- Procedure: Group S : Stellate Ganglion supervoltage pulsed radiofrequency
- Procedure: Group T : T2-T3 chains supervoltage pulsed radiofrequency.
- Sponsor
- National Cancer Institute, Egypt
- Start date
- 2026-07-01
- Primary completion
- 2027-07-30
- Sex
- Female
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Female patients aged 18-60 years. * Patient of class II according to the American society of Anesthesiologists (ASA) physical status classification system. * History of unilateral mastectomy for breast cancer. * Persistent pain \>3 months postoperatively. * VAS score ≥4 despite pharmacological management. * Patients with neuropathic pain who has a score ≥4 by (DN4) questionnaire. * Patients on more than 1 antineuropathic drug. Exclusion Criteria: * Coagulopathy or anticoagulant therapy. * Local infection at injection site. * History of psychiatric illness or cognitive dysfunction. * Previous intervention in the same region (e.g., prior stellate ganglion block or thoracic radiofrequency ablation). * Allergy to local anesthetics or contrast agents.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07675096